Everest Medicines Announces Partner Providence Reports Positive Top-Line Data from Phase 2 Primary Immunization Trial for mRNA COVID-19 Vaccine Candidate in Adults
yahoo.com
science
2022-10-19 12:15:00

-- Levels of neutralizing antibodies generated by PTX-COVID19-B were non-inferior to ComirnatyÂ®--

-- PTX-COVID19-B was well tolerated with no safety signals--

-- Everest is filing IND applications for phase 3 clinical trials for booster indication--

SHANGHAI, Oct. 19, 2022 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products to address critical unmet needs in Asia Pacific markets, announced today that its partner Providence Therapeutics Holdings Inc.
